Compare · ADVB vs ILMN
ADVB vs ILMN
Side-by-side comparison of Advanced Biomed Inc. (ADVB) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADVB and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $40.46B, about 5018.0x ADVB ($8.1M).
- Over the past year, ADVB is down 46.8% and ILMN is up 174.9% - ILMN leads by 221.7 points.
- ILMN has been more active in the news (8 items in the past 4 weeks vs 2 for ADVB).
- ILMN has more recent analyst coverage (25 ratings vs 0 for ADVB).
- Company
- Advanced Biomed Inc.
- Illumina Inc.
- Price
- $5.11-3.58%
- $262.52-2.06%
- Market cap
- $8.1M
- $40.46B
- 1M return
- -37.68%
- +7.01%
- 1Y return
- -46.84%
- +174.89%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 2
- 8
- Recent ratings
- 0
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ADVB
- SEC Form 10-K filed by Advanced Biomed Inc.
- SEC Form NT 10-K filed by Advanced Biomed Inc.
- Large owner Pau Hung To disposed of $84,588,000,000 worth of Common Stock par vlaue $0.001 (176,225 units at $480,000.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form RW filed by Advanced Biomed Inc.
- Advanced Biomed Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- Advanced Biomed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Advanced Biomed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Advanced Biomed Inc.
- SEC Form 10-Q filed by Advanced Biomed Inc.
- Advanced Biomed Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)